Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06357507
Other study ID # hayam hamdy
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date December 1, 2024
Est. completion date December 20, 2027

Study information

Verified date April 2024
Source Assiut University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

moraxella catarrhalis is responsible for respiratory tract infection in children and adults with streptococcus pneumonia and haemophilus influenza.Moraxella catarrhalis is gram negative diplococci, non-motile and non spore bearing bacteria. Until, 1995 it was considered as a non pathogenic respiratory tract flora.This bacteria is an important pathogen and a common cause of both upper and lower respiratory tract infections, pneumonia, sinusitis and conjunctivitis in infants, children and in elderly patients. In adults, M. catarrhalis also causes chronic obstructive pulmonary disease (COPD) and pneumonia. However, it is associated with a number of respiratory infections affecting both children and adults, including laryngitis, bronchitis and pneumonia .


Description:

This institution is polymicrobial community with other pathogens such as Streptococcus pneumoniae and Haemophilus influenza (Sethi and Murphy, 2008). The pathogenicity of M. catarrhalis is mediated by several virulence genes, including the ubiquitous surface protein genes A1 (uspA1) and A2 (uspA2), which encode virulence factors that promote colonization and successful host infections (Bernhard S et al.,2012).Bacterium was first isolated in 1896, it was considered to be a harmless commensal of the upper respiratory tract for a long period of time. The bacterium rapidly colonizes the nasopharynx soon after birth asymptomatically (Blakeway et al., 2017).


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 90
Est. completion date December 20, 2027
Est. primary completion date December 1, 2027
Accepts healthy volunteers No
Gender All
Age group 1 Month and older
Eligibility Inclusion Criteria: - all children with bacterial pneumonia Exclusion Criteria: - viral pneumonia , tuberculosis and immunocompromised

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

References & Publications (3)

Bernhard S, Spaniol V, Aebi C. Molecular pathogenesis of infections caused by Moraxella catarrhalis in children. Swiss Med Wkly. 2012 Oct 29;142:w13694. doi: 10.4414/smw.2012.13694. eCollection 2012. — View Citation

Blakeway LV, Tan A, Peak IRA, Seib KL. Virulence determinants of Moraxella catarrhalis: distribution and considerations for vaccine development. Microbiology (Reading). 2017 Oct;163(10):1371-1384. doi: 10.1099/mic.0.000523. Epub 2017 Sep 12. — View Citation

Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008 Nov 27;359(22):2355-65. doi: 10.1056/NEJMra0800353. No abstract available. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary isolation of moraxella catarrhalis isolation of organism on muller hinton agar 3 years
Secondary detection of virulence genes of moraxella catarrhalis detection of virulence genes by PCR 3 years
Secondary detetion of antibiotic resistance detetion of antibiotic resistance by agar disc diffusion 3years
See also
  Status Clinical Trial Phase
Completed NCT05525494 - Patient Portal Flu Vaccine Reminders (5) N/A
Completed NCT04537663 - Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults Phase 4
Terminated NCT04583280 - A Study of Rilematovir in Infants and Children and Subsequently in Neonates Hospitalized With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus (RSV) Phase 3
Completed NCT03321968 - Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults Phase 3
Active, not recruiting NCT03251196 - TB Sequel: Pathogenesis and Risk Factors of Long-term Sequelae of Pulmonary TB
Completed NCT02561871 - A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad26.RSV.FA2 Followed by Ad35.RSV.FA2 in Healthy Adult Volunteers Phase 1
Completed NCT01911143 - A Retrospective, Blinded Validation of a Host-response Based Diagnostics N/A
Terminated NCT02032056 - Effect of Probiotics in Reducing Infections and Allergies in Young Children During the Complementary Feeding Period N/A
Completed NCT01419262 - DO IT Trial: Vitamin D Outcomes and Interventions In Toddlers Phase 3
Terminated NCT01432080 - Steroids, Azithromycin, Montelukast, and Symbicort (SAMS) for Viral Respiratory Tract Infection Post Allotransplant Phase 2
Completed NCT00984945 - Safety Study of a Plant-based H5 Virus-Like Particles (VLP) Vaccine in Healthy Adults Phase 1
Completed NCT00127686 - Effect of Honey and Dextromethorphan on Nocturnal Cough and Sleep Phase 1
Active, not recruiting NCT01107223 - Long Term Effect of General Practitioner Education on Antibiotic Prescribing N/A
Completed NCT03739112 - Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly Phase 3
Completed NCT04144491 - Effect of L. Rhamnosus Yoba on RTI and Other Health Outcomes Among Children (3-6 Years) in Uganda N/A
Completed NCT05318235 - Virus Interactions in the Respiratory Tract; a Cohort Study With Children
Active, not recruiting NCT04170348 - Daily Vitamin D for Sickle-cell Respiratory Complications Phase 2
Completed NCT04525040 - ProbioKid as Prevention Among Kids With Frequent URTI N/A
Completed NCT05535777 - Patient Portal Flu Vaccine Reminders_RCT 5 (LADHS) N/A
Not yet recruiting NCT05914324 - Outpatient Pediatric Pulse Oximeters in Africa N/A